Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

SMILE Surgery in One Eye Compared to Ray Tracing-guided LASIK Surgery in the Fellow Eye

24. august 2026 oppdatert av: Edward E. Manche, Stanford University

A Prospective Randomized Comparison of SMILE Surgery to Ray Tracing-Guided LASIK Surgery

Participants will undergo LASIK surgery in one eye using ray tracing guided technology in one eye and LASIK surgery in the other eye using wavefront guided technology. We are comparing outcomes between the two technologies as measured by self reported quality of vision and quality of life outcomes using validated questionnaires before and after surgery. We will also be comparing outcomes between the two technologies including measurement of low contrast visual acuity,and best spectacle corrected visual acuity.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

Sixty-two near-sighted study participants at Stanford are planned to undergo treatment in this clinical research trial.

This comparison will be made between both eyes of the same study participant following LASIK and SMILE surgery. One eye will have ray tracing-guided LASIK and their fellow eye treated with SMILE surgery. Both ray tracing-guided LASIK surgery and SMILE surgery have been found to be safe, predictable and effective when used for laser vision correction procedures. Both ray tracing-guided LASIK surgery and SMILE surgery used in this study have been approved for laser vision correction by the United States Food and Drug Administration. Standard refractive outcomes such as uncorrected visual acuity (vision without glasses or contact lenses) and best corrected visual acuity (vision with glasses or contact lenses), and intended vs. achieved postoperative refractions (the accuracy of the LASIK and SMILE procedures) will be evaluated.

Randomization:

The choice of which eye receives ray tracing-guided LASIK surgery and which eye receives SMILE surgery will be randomized (assigned at random) prior to enrollment. Participants will have one eye treated with ray tracing-guided LASIK and your other eye treated with the SMILE surgery. Participants will know which eye is being treated with ray tracing-guided LASIK and which eye will be treated with SMILE surgery. Both ray tracing-guided LASIK and SMILE surgery are FDA-approved procedures. Both procedures are being performed according to the FDA-approved labeling. Participants have a fifty percent chance of having their left eye treated with ray tracing-guided LASIK as their right eye (like making a choice by flipping a coin). Participants will undergo bilateral (both eyes at once) surgery.

Screening and Preoperative Assessment Participants will be partially screened via telephone. We will also ask participants to complete screening by coming to the clinic in person. This screening will include measurements of corneal thickness, the shape of the cornea using corneal topography (measures the shape of the front clear surface of the eye), a slit lamp examination of the eye (a microscope to magnify the cornea) and ocular and medical history.

Participants scheduled to undergo LASIK and SMILE surgery for the correction of myopia (nearsightedness) will be screened for eligibility. Eligible participants will be examined preoperatively to establish a baseline for ocular condition (the general health and glasses prescription of the eyes). Postoperatively, participants will undergo an ophthalmic evaluation (complete eye examination) at regular intervals as specified in this protocol. Re-treatments (a second operation on the same eye for residual nearsightedness, farsightedness and/or astigmatism) will not be allowed during the first twelve months of this study. If you elect to undergo a retreatment of your LASIK surgery prior to the 12-month post-operative visit, the data after the retreatment procedure will be excluded from the study analysis.

Participants eyes will be given a thorough examination at each visit. This examination will include the standard elements of a general eye exam including testing of the eye's vision, contrast acuity testing, examination with the slit lamp and the ophthalmoscope to look at the various parts of the eye and a test of the inner eye's pressure.

Studietype

Intervensjonell

Registrering (Antatt)

62

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Palo Alto, California, Forente stater, 94303
        • Rekruttering
        • Byers Eye Institute
        • Hovedetterforsker:
          • Edward E Manche, MD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

Subjects age 22 and older with healthy eyes. Nearsightedness between -1.00 diopters and -8.00 diopters.

Subjects with less than or equal to 3.00 diopters of astigmatism.

Exclusion Criteria:

Subjects under the age of 22. Subjects with excessively thin corneas. Subjects with topographic evidence of keratoconus. Subjects with ectactic eye disorders. Subjects with autoimmune diseases. Subjects who are pregnant or nursing. Subjects must have similar levels of nearsightedness in each eye. They can not be more than 1.5 diopter of difference between eyes.

Subjects with more than 3.00 diopters of astigmatism Subjects must have similar levels of astigmatism in each eye. They can not have more than 0.75 diopters of difference between eyes.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Ray tracing guided LASIK surgery
LASIK
LASIK
Aktiv komparator: SMILE surgery
SMILE
LASIK

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in corrected distance visual acuity
Tidsramme: Three months
The primary endpoint will be the gain in lines of corrected distance visual acuity (CDVA) at the postoperative month three follow-up compared with preoperative baseline.
Three months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in 5 and 25% low contrast CDVA
Tidsramme: Three months
Change in 5 and 25% low contrast best corrected visual acuity from preoperative to postoperative month three
Three months
Change in patient self reported quality of vision and life
Tidsramme: Three months
Will compare preoperative quality of vision and quality of life as measured by the validated Patient Reported Outcomes With LASIK (PROWL) questionnaire to postoperative month three.
Three months
Corneal epithelial thickness changes
Tidsramme: Three months
Measure corneal epithelial thickness maps preoperatively and compare changes at postoperative month three
Three months
Change in higher order aberrations
Tidsramme: Three months
Will measure preoperative higher order aberrations using wavefront aberrometry and compare to postoperative month three measurements
Three months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. august 2026

Primær fullføring (Antatt)

31. desember 2028

Studiet fullført (Antatt)

31. juli 2029

Datoer for studieregistrering

Først innsendt

18. juli 2026

Først innsendt som oppfylte QC-kriteriene

18. juli 2026

Først lagt ut (Faktiske)

23. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

26. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 79951
  • 359910 (Annet stipend/finansieringsnummer: Alcon)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere